Following on from the module Early Drug Discovery Research, the focus of this module is the further pre-clinical development of drugs or diagnostic tests. The module will examine how lead candidate molecules are identified, whether that is through in house development, licensing-in, or compound re-profiling. The highly important processes of pharmacological (ADME), toxicological testing, and compound formulation of lead compounds will be addressed. The design of clinical trials and pharmacovigilance will also be examined, highlighting the need for robust ethical and toxicological considerations. Finally, the module will inform about the regulatory approval processes involved for drug clinical assessment (IND application), the NDA submission, and potential marketing strategies.
20 Masters level credits
Module attendance required
TBC, 30 hours contact time with lectures and small group teaching sessions
This module will require a 3000 word analysis of a case study worth 35%, an ICA short answer of 1500-2000 words worth 30% and an oral presentation worth 35%
Academics involved in the delivery of this module
- Dr Paul Foster (Deputy Programme Lead, Module Lead, and Lecturer in Molecular Endocrinology) – University of Birmingham
- Dr. Tim Overton (Lecturer in Chemical Engineering) – University of Birmingham
How to register/apply
Contact our Course Administrator:
(0121) 415 8118
Please rest assured that we will make all reasonable efforts to provide you with the courses, services and facilities described. However, it may be necessary to make changes due to significant disruption, for example in response to COVID-19.
Information for future students and applicants
Coronavirus (COVID-19) latest updates and FAQs for future students and offer-holdersVisit our FAQs